Evidence map›Paper›PMID 40841135›Full record

ArticleBJGP open2026

Personalising renal function monitoring and interventions in people living with heart failure: a protocol for co-designing a care pathway in the RENAL-HF programme.

Suzy C Hargreaves, Christopher J Armitage, Benjamin C Brown, Dawn Dowding, Jennifer Downing, Mark Goodall, Alison Gummery, Carolyn Lees, Emma Sowden, Nefyn H Williams and 3 more

Abstract read
In one paragraph

Article in BJGP open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Suzy C HargreavesDepartment of Primary Care and Mental Health, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom s.c.hargreaves@liverpool.ac.uk.ORCID https://orcid.org/0000-0003-3240-8230
Christopher J ArmitageManchester Centre for Health Psychology. University of Manchester and NIHR Greater Manchester, Patient Safety Research Collaboration, University of Manchester, Manchester, United Kingdom.
Benjamin C BrownSchool of Health Sciences, University of Manchester, Manchester, United Kingdom.
Dawn DowdingSchool of Health Sciences, University of Manchester, Manchester, United Kingdom.
Jennifer DowningDepartment of Primary Care and Mental Health, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.
Mark GoodallDepartment of Primary Care and Mental Health, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.
Alison GummeryDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
Carolyn LeesSchool of Allied Health Professions and Nursing, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.
Emma SowdenSchool of Health Sciences, University of Manchester, Manchester, United Kingdom.
Nefyn H WilliamsDepartment of Primary Care and Mental Health, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.ORCID https://orcid.org/0000-0002-8078-409X
Bridget YoungDepartment of Public Health, Policy and Systems, Institute of Population Health, University of Liverpool, Liverpool, United Kingdom.
Munir PirmohamedDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
RENAL-HF Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeart failure affects almost one million people in the UK and is increasing in prevalence. Many drugs used to treat heart failure impair renal function and can lead to hospitalisation. Adverse drug problems can be partially mitigated through regular renal monitoring and optimising of drug dose and choice to prevent deterioration of kidney function. This protocol describes part of a wider research programme: personalising renal function monitoring and interventions in people living with heart failure (RENAL-HF).

aimThe aim of RENAL-HF is to develop improved processes in primary care to manage kidney health in people living with heart failure.

methodThe protocol covers gathering views of healthcare professionals, patients, and carers, to co-develop a care pathway for use in primary care. Using a mixed-methods approach, the work comprises the following six stages: (1) understanding current practice of optimising heart failure treatment while preserving renal function; (2) co-designing a care pathway including personalised renal function monitoring, thresholds for intervention and clinical guidelines; (3) decision making to identify elements that will support the care pathway; (4) developing training materials for primary care to enable use of the care pathway; (5) testing the usability of the prototype care pathway; and 6) a feasibility and acceptability study to inform the pre-clinical development and usability of the care pathway ahead of a cluster randomised control trial (RCT).

conclusionAll stages will elicit evidence from primary care practices, practitioners, and patients with which to assess and refine the care pathway. The evidence will inform how algorithm-guided individualised treatment can be implemented to improve the outcomes of patients with heart failure.

Indexed as

general practitionersheart failureoptimising careprimary healthcarerenal function

Identifiers

PMID40841135
PMCPMC13540360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.